Investigational drug · Phase 3
Adebrelimab
Also called: SHR-8068, HRS -4642, SHR-4610
Not approved by FDA. In 41 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
41
41 still active
All registered trials
301
Any phase or sponsor naming "Adebrelimab"
First trial start
2024
Mar 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Adebrelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Solid Tumors
- Carcinoma, Non-Small-Cell Lung
- Non-squamous Non-small Cell Lung Cancer
- Advanced Esophageal Squamous Cell Carcinoma
- Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Pancreatic Cancer
- Malignant Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Adebrelimab" as an intervention, largest first.
- A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung CancerStatus unknown
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06530797 · 2,000 participants (planned) · Start Aug 1, 2024 · Primary completion Sep 1, 2026
Drug: First-line Adebrelimab regiment for advanced stage ES-SCLC; Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC · For: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLCPivotal-lookingNot yet recruiting
West China HospitalAcademic, hospital or other
NCT07895238 · 1,088 participants (planned) · Start Oct 31, 2026 · Primary completion Dec 31, 2032
Drug: Adebrelimab (SHR-1316) + chemotherapy; Adebrelimab · For: Non-small Cell Lung Cancer (NSCLC)
Hansoh BioMedical R&D CompanyIndustry
NCT06336707 · 1,048 participants (planned) · Start Apr 11, 2024 · Primary completion Apr 8, 2026
Drug: HS-20089; Adebrelimab and 2 more · For: Advanced Solid Tumors
Sites: Shanghai, China
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerPivotal-lookingRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07679360 · 1,000 participants (planned) · Start Sep 2, 2026 · Primary completion Dec 2030
Drug: Trastuzumab Rezetecan for Injection; Adebrelimab Injection and 2 more · For: Triple Negative Breast Cancer
Sites: Beijing, China
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07645209 · 1,000 participants (planned) · Start May 13, 2026 · Primary completion May 13, 2028
Drug: Immune Checkpoint Inhibitors · For: Liver Cancer
Sites: Harbin, China
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT06350006 · 924 participants (planned) · Start May 29, 2024 · Primary completion Dec 30, 2027
Drug: SHR-A1904; Adebrelimab; SHR-A1904; CAPOX; Adebrelimab · For: CLDN18.2-positive Advanced Solid Tumor
Sites: Guangzhou, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06703177 · 876 participants (planned) · Start Feb 18, 2025 · Primary completion Jan 1, 2026
Drug: SHR-1826; SHR-4642 and 7 more · For: Advanced Solid Tumors
Sites: Guangzhou, China
- Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction CancerPivotal-lookingRecruiting
Shanghai Shengdi Pharmaceutical Co., LtdIndustry
NCT07522151 · 874 participants (planned) · Start May 7, 2026 · Primary completion Dec 2029
Drug: Adebrelimab plus S-1 and oxaliplatin; Adebrelimab blank preparation plus S-1 and oxaliplatin. · For: Locally Advanced Gastric or Gastroesophageal Junction Cancer
Sites: Beijing, China
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06963502 · 762 participants (planned) · Start May 30, 2025 · Primary completion Dec 31, 2028
Drug: HS-10370; HS-20117 and 6 more · For: Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer
Sites: Hangzhou, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?
Min J, Liu L, Sun SQ, et al. · Future Sci OA 2026
- KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.
Zhang Y, Tang S, Zhang Y, et al. · Cancer Cell 2026
- Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.
Xie H, Wang G, Yuan Z, et al. · Cancer Lett 2026
- No recurrent severe immune-related hepatitis during PD-L1 therapy after PD-1-related hepatitis in advanced gastroesophageal junction adenocarcinoma: a case report.
Yu K, Jia Y, Chen H, et al. · Semin Oncol 2026
- The consolidation paradox: rethinking thoracic radiotherapy in extensive-stage small cell lung cancer in the immunotherapy era.
Ciammella P, Alì E, Iori F · Front Oncol 2026
- Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial.
Jin Y, Lu W, Lou L, et al. · BMJ Open 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.